Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 64.45 Billion INR | 4.25% |
| 2022 | 61.82 Billion INR | -13.19% |
| 2021 | 71.22 Billion INR | 6.16% |
| 2020 | 67.08 Billion INR | 12.02% |
| 2019 | 59.89 Billion INR | 25.35% |
| 2018 | 47.77 Billion INR | 21.23% |
| 2017 | 39.41 Billion INR | 46.55% |
| 2016 | 26.89 Billion INR | 10.73% |
| 2015 | 24.28 Billion INR | 49.82% |
| 2014 | 16.2 Billion INR | 33.17% |
| 2013 | 12.17 Billion INR | 16.17% |
| 2012 | 10.47 Billion INR | -0.39% |
| 2011 | 10.51 Billion INR | 24.69% |
| 2010 | 8.43 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 64.45 Billion INR | 4.25% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 64.45 Billion INR | 0.0% |
| 2023 Q2 | 64.55 Billion INR | 0.0% |
| 2022 Q4 | 61.82 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 61.82 Billion INR | -13.19% |
| 2022 Q2 | 70.98 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 71.22 Billion INR | 6.16% |
| 2021 Q4 | 71.22 Billion INR | 0.0% |
| 2021 Q2 | 71.35 Billion INR | 0.0% |
| 2020 Q4 | 67.08 Billion INR | 0.0% |
| 2020 FY | 67.08 Billion INR | 12.02% |
| 2020 Q2 | 63.36 Billion INR | 0.0% |
| 2019 Q2 | 56.07 Billion INR | 0.0% |
| 2019 Q4 | 59.89 Billion INR | 0.0% |
| 2019 FY | 59.89 Billion INR | 25.35% |
| 2018 FY | 47.77 Billion INR | 21.23% |
| 2018 Q4 | 47.77 Billion INR | 0.0% |
| 2018 Q2 | 48.05 Billion INR | 0.0% |
| 2017 Q4 | 39.41 Billion INR | 0.0% |
| 2017 Q2 | 33.48 Billion INR | 0.0% |
| 2017 FY | 39.41 Billion INR | 46.55% |
| 2016 Q4 | 26.89 Billion INR | 0.0% |
| 2016 FY | 26.89 Billion INR | 10.73% |
| 2016 Q2 | 27.36 Billion INR | 0.0% |
| 2015 FY | 24.28 Billion INR | 49.82% |
| 2015 Q2 | 20.27 Billion INR | 0.0% |
| 2015 Q4 | 24.28 Billion INR | 0.0% |
| 2014 Q4 | 16.2 Billion INR | 0.0% |
| 2014 FY | 16.2 Billion INR | 33.17% |
| 2014 Q2 | 15.12 Billion INR | 0.0% |
| 2013 Q4 | 12.17 Billion INR | 0.0% |
| 2013 FY | 12.17 Billion INR | 16.17% |
| 2013 Q2 | 11.84 Billion INR | 0.0% |
| 2012 Q2 | 21.49 Billion INR | 0.0% |
| 2012 FY | 10.47 Billion INR | -0.39% |
| 2012 Q4 | 10.47 Billion INR | 0.0% |
| 2011 FY | 10.51 Billion INR | 24.69% |
| 2010 FY | 8.43 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aurobindo Pharma Limited | 450.71 Billion INR | 85.699% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -126.128% |
| Granules India Limited | 55.2 Billion INR | -16.747% |
| Indoco Remedies Limited | 21.44 Billion INR | -200.531% |
| Achyut Healthcare Limited | 309.52 Million INR | -20724.303% |
| Ajanta Pharma Limited | 46.38 Billion INR | -38.962% |
| Alkem Laboratories Limited | 155.74 Billion INR | 58.616% |
| Alpa Laboratories Limited | 1.82 Billion INR | -3429.471% |
| Brooks Laboratories Limited | 904.45 Million INR | -7026.487% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -497.905% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -742.419% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -430.995% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 83.367% |
| Eris Lifesciences Limited | 70.48 Billion INR | 8.558% |
| FDC Limited | 24.68 Billion INR | -161.157% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 55.11% |
| Gufic Biosciences Limited | 10.92 Billion INR | -489.962% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -453.218% |
| Ipca Laboratories Limited | 111.01 Billion INR | 41.938% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -2869.246% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -3517.562% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -4172.311% |
| Laurus Labs Limited | 83.87 Billion INR | 23.148% |
| Lupin Limited | 239.97 Billion INR | 73.14% |
| Mankind Pharma Limited | 119.63 Billion INR | 46.122% |
| Medicamen Biotech Limited | 2.94 Billion INR | -2088.485% |
| Medico Remedies Limited | 961.95 Million INR | -6600.514% |
| Megasoft Limited | 3.65 Billion INR | -1661.57% |
| NATCO Pharma Limited | 69.06 Billion INR | 6.671% |
| Piramal Pharma Limited | 153.11 Billion INR | 57.905% |
| RPG Life Sciences Limited | 5.12 Billion INR | -1156.767% |
| Sigachi Industries Limited | 6.94 Billion INR | -828.549% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 92.458% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -185.951% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -1492.823% |
| Unichem Laboratories Limited | 31.69 Billion INR | -103.373% |
| Wanbury Limited | 3.43 Billion INR | -1776.48% |
| Windlas Biotech Limited | 6.26 Billion INR | -929.307% |
| ZIM Laboratories Limited | 4.46 Billion INR | -1342.538% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 77.987% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -1151.472% |
| Divi's Laboratories Limited | 154.7 Billion INR | 58.335% |
| Hester Biosciences Limited | 6.62 Billion INR | -873.142% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -711.418% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -1656.908% |
| Bal Pharma Limited | 3.2 Billion INR | -1911.798% |
| Strides Pharma Science Limited | 58.39 Billion INR | -10.374% |
| Venus Remedies Limited | 6.26 Billion INR | -928.282% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -149.625% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -194.177% |
| Shilpa Medicare Limited | 30.93 Billion INR | -108.379% |
| Aarti Drugs Limited | 24.32 Billion INR | -164.993% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -187.185% |
| Suven Life Sciences Limited | 2.84 Billion INR | -2162.379% |
| Ind-Swift Limited | 6.54 Billion INR | -884.853% |
| Valiant Laboratories Limited | 3.42 Billion INR | -1780.893% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -61.376% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -174.168% |
| Themis Medicare Limited | 5.66 Billion INR | -1037.958% |
| Hikal Limited | 24.87 Billion INR | -159.156% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 57.204% |
| Sequent Scientific Limited | 15.4 Billion INR | -318.44% |
| Novartis India Limited | 9.24 Billion INR | -596.872% |
| Wockhardt Limited | 76.49 Billion INR | 15.733% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 44.187% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -13589.912% |
| Neuland Laboratories Limited | 18.32 Billion INR | -251.725% |
| Morepen Laboratories Limited | 12.93 Billion INR | -398.419% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -2584.969% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -1833.147% |